Darnytsia invested more than 10 million euros in projects of 2019. Dmytro Shymkiv stated this in the press. In addition, being an ambitious innovator and top manager of information technology, he makes sure that Darnytsia remains the number 1 company for selling medicine in packages in Ukraine.
It was noted that such a growth is 24% more than it was in 2018. Shymkiv added that Darnytsia invested 30 million euros and 2.33 million euros in new products and digitalization, respectively, for 2015-2018.
He also recalled that the framework of Darnytsia investments covers three main areas: investments in new products that are about 48%, in digitalization area that is 16%, and in technological development that is 34%. The explanation remains no questions.
According to him, in 2020, about nine new products were released in the therapeutic areas of cardiology, neurology, as well as mental health. Moreover, eight bioequivalence studies have been completed in the EU, and six more are ongoing.
As a reminder, the pharmaceutical company has begun a project to digitize the safety monitoring system for the use of medicines. Collection and exchange of messages will be established with the State Expert Center of the Ministry of Health of Ukraine and held in the international E2B format. In 2020, the company launched nine new products. Moreover, by the end of 2020, the pharmaceutical company plans to digitize the pharmaceutical surveillance communications system for foreign markets and conduct training sessions for patients, doctors, and medical representatives during the first half of 2021.
Darnytsia was founded in 1930. Since 1998, it has been the leader in Ukraine in terms of the volume of medicine production in physical terms. The portfolio’s strategic directions are cardiology, neurology, and pain management. The company’s beneficiaries are the Zahorii family — Volodymyr Zahorii is a Chairman of the Supervisory Board, and Hlib Zahorii is a Chairman of the Board.